Ex vivo limb perfusion for traumatic amputation in military medicine.
Journal
Military Medical Research
ISSN: 2054-9369
Titre abrégé: Mil Med Res
Pays: England
ID NLM: 101643181
Informations de publication
Date de publication:
26 04 2020
26 04 2020
Historique:
received:
22
07
2019
accepted:
15
04
2020
entrez:
27
4
2020
pubmed:
27
4
2020
medline:
31
3
2021
Statut:
epublish
Résumé
Limb loss has a drastic impact on a patient's life. Severe trauma to the extremities is common in current military conflicts. Among other aspects, "life before limb" damage control surgery hinders immediate replantation within the short post-traumatic timeframe, which is limited in part by the ischemic time for successful replantation. Ex vivo limb perfusion is currently being researched in animal models and shows promising results for its application in human limb replantation and allotransplantation. The current lack of replantation possibilities in military operations with high rates of amputation can be addressed with the development of a portable ex vivo limb perfusion device, as there are several opportunities present with the introduction of this technique on the horizon. We hypothesize that ex vivo limb perfusion will enable overcoming the critical ischemic time, provide surgical opportunities such as preparation of the stump and limb, allow for spare-part surgery, enable rigorous antibiotic treatment of the limb, reduce ischemia-reperfusion injuries, enable a tissue function assessment before replantation, and enable the development of large limb transplant programs. Data from in vivo studies in porcine models are limited by the relatively short perfusion time of 24 h. In the military setting, notably longer perfusion times need to be realized. Therefore, future animal studies must focus especially on long-term perfusion, since this represents the military setting, considering the time for stabilization of the patient until evacuation to a tertiary treatment center. The development and clinical introduction of ex vivo limb perfusion in the military setting could lead to a drastic reduction in the number of limb amputations among service members. Ex vivo limb perfusion enables replantation surgery in Role 4 facilities and changes the clinical setting from a highly urgent, life-threatening situation to a highly methodical, well-prepared starting point for optimal treatment of the wounded service member. With its introduction, the principle of "life before limb" will change to "life before limb before elective replantation/allotransplantation after ex vivo limb perfusion".
Sections du résumé
BACKGROUND
Limb loss has a drastic impact on a patient's life. Severe trauma to the extremities is common in current military conflicts. Among other aspects, "life before limb" damage control surgery hinders immediate replantation within the short post-traumatic timeframe, which is limited in part by the ischemic time for successful replantation. Ex vivo limb perfusion is currently being researched in animal models and shows promising results for its application in human limb replantation and allotransplantation.
PRESENTATION OF THE HYPOTHESIS
The current lack of replantation possibilities in military operations with high rates of amputation can be addressed with the development of a portable ex vivo limb perfusion device, as there are several opportunities present with the introduction of this technique on the horizon. We hypothesize that ex vivo limb perfusion will enable overcoming the critical ischemic time, provide surgical opportunities such as preparation of the stump and limb, allow for spare-part surgery, enable rigorous antibiotic treatment of the limb, reduce ischemia-reperfusion injuries, enable a tissue function assessment before replantation, and enable the development of large limb transplant programs.
TESTING THE HYPOTHESIS
Data from in vivo studies in porcine models are limited by the relatively short perfusion time of 24 h. In the military setting, notably longer perfusion times need to be realized. Therefore, future animal studies must focus especially on long-term perfusion, since this represents the military setting, considering the time for stabilization of the patient until evacuation to a tertiary treatment center.
IMPLICATIONS OF THE HYPOTHESIS
The development and clinical introduction of ex vivo limb perfusion in the military setting could lead to a drastic reduction in the number of limb amputations among service members. Ex vivo limb perfusion enables replantation surgery in Role 4 facilities and changes the clinical setting from a highly urgent, life-threatening situation to a highly methodical, well-prepared starting point for optimal treatment of the wounded service member. With its introduction, the principle of "life before limb" will change to "life before limb before elective replantation/allotransplantation after ex vivo limb perfusion".
Identifiants
pubmed: 32334640
doi: 10.1186/s40779-020-00250-y
pii: 10.1186/s40779-020-00250-y
pmc: PMC7183706
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Références
Angew Chem Int Ed Engl. 2009;48(20):3584-96
pubmed: 19212993
Tissue Eng Part A. 2014 Sep;20(17-18):2339-49
pubmed: 24606318
J Hand Surg Am. 2017 Dec;42(12):1019-1024
pubmed: 29054354
Circulation. 2008 Jul 8;118(2):166-75
pubmed: 18591435
J Clin Diagn Res. 2016 Sep;10(9):RC09-RC12
pubmed: 27790532
J Mater Sci Mater Med. 2017 May;28(5):72
pubmed: 28361279
Arch Phys Med Rehabil. 2008 Mar;89(3):422-9
pubmed: 18295618
BMC Musculoskelet Disord. 2017 Feb 10;18(1):77
pubmed: 28187720
Liver Transpl. 2013 Nov;19(11):1252-61
pubmed: 24106037
Injury. 2016 Dec;47(12):2783-2788
pubmed: 28029356
J Trauma. 2008 Feb;64(2):295-9
pubmed: 18301189
J Surg Res. 2011 Nov;171(1):291-9
pubmed: 20451920
J Hand Surg Am. 2016 Jan;41(1):3-12
pubmed: 26710728
J Surg Res. 2018 Dec;232:137-145
pubmed: 30463709
Lancet Child Adolesc Health. 2017 Sep;1(1):35-44
pubmed: 30169225
Orthop Clin North Am. 2010 Apr;41(2):233-9
pubmed: 20399362
Lancet Respir Med. 2018 May;6(5):357-367
pubmed: 29650408
Instr Course Lect. 2008;57:65-86
pubmed: 18399571
Biomed Tech (Berl). 2013 Sep 7;58 Suppl 1:
pubmed: 24042684
Innov Surg Sci. 2017 Aug 08;2(4):171-187
pubmed: 31579751
Plast Reconstr Surg Glob Open. 2018 Jun 11;6(6):e1825
pubmed: 30276052
Injury. 2016 Aug;47(8):1806-10
pubmed: 27287739
J Surg Res. 2013 May 1;181(1):170-82
pubmed: 22748598
J Bone Joint Surg Am. 2013 Jan 16;95(2):138-45
pubmed: 23324961
J Trauma Acute Care Surg. 2019 Jul;87(1S Suppl 1):S172-S177
pubmed: 31246923
Injury. 2012 Oct;43(10):1678-82
pubmed: 22769977
Lancet. 2012 Nov 24;380(9856):1851-8
pubmed: 23063317
Hum Gene Ther. 2019 Apr;30(4):485-496
pubmed: 30261752
Int J Dermatol. 1995 Apr;34(4):290-2
pubmed: 7790149
Ann Transplant. 2013 Dec 18;18:685-96
pubmed: 24346057
BMC Neurosci. 2017 Jul 18;18(1):53
pubmed: 28720074
Med Mal Infect. 2018 Sep;48(6):403-409
pubmed: 29709404
Plast Reconstr Surg. 2017 Apr;139(4):922e-932e
pubmed: 28350667
PLoS One. 2017 Jan 25;12(1):e0170569
pubmed: 28122002
Nature. 2018 May;557(7703):50-56
pubmed: 29670285
Biomed Res Int. 2014;2014:906819
pubmed: 24949480
Transplantation. 2017 Mar;101(3):e68-e74
pubmed: 28222055
PLoS One. 2018 Mar 5;13(3):e0193168
pubmed: 29505574
PLoS One. 2011 Feb 25;6(2):e16990
pubmed: 21364921
Unfallchirurg. 2016 May;119(5):358-73
pubmed: 27178157